Form 4: Enliven Therapeutics Chief Scientific Officer Sells Shares Under Pre-Arranged Trading Plan

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 12,500 shares of common stock for approximately $278,000 through a pre-established Rule 10b5-1 trading plan.

Summary

• Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), reported the sale of common stock.
• A total of 12,500 shares were sold on July 21, 2025, pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.
• The first tranche involved 11,924 shares sold at a weighted average price of $22.2625 per share, with prices ranging from $21.81 to $22.805.
• The second tranche involved 576 shares sold at a weighted average price of $22.8954 per share, with prices ranging from $22.81 to $23.025.
• Following these transactions, Joseph P. Lyssikatos beneficially owns 952,688 shares of common stock.
• The shares beneficially owned are held indirectly by The Lyssikatos Revocable Trust 12/15/2011, for which the Reporting Person serves as trustee.

Sentiment

Score: 6

Explanation: While insider selling can be perceived negatively, the transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the sale was not based on new, non-public information and was part of a planned liquidity event, thus mitigating significant negative sentiment.

Positives

• The stock sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan, adopted well in advance on November 15, 2024, which indicates the transactions were scheduled and not based on new, non-public information.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived by the market as a signal of management's outlook on the company's valuation or future prospects.

Risks

• Potential for negative market perception or short-term stock price volatility due to the reported insider sale, despite it being part of a pre-arranged plan.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The remaining 952,688 shares are held indirectly by The Lyssikatos Revocable Trust 12/15/2011, for which the Reporting Person serves as trustee, indicating beneficial ownership through a related party entity.

Stakeholder Impact

• Shareholders might interpret the insider sale, even if planned, as a signal about management's view on future stock performance, potentially leading to minor short-term price fluctuations.

Key Dates

Recommendation

The insider sale, while a reduction in direct ownership, was conducted under a pre-established Rule 10b5-1 trading plan. This suggests it was a planned liquidity event rather than a reaction to new negative information. This mitigates the typical negative signal of insider selling, leading to a neutral 'hold' recommendation as the filing itself does not provide new fundamental information to warrant a change in investment thesis.

Keywords

Enliven Therapeutics, ELVN, Joseph P Lyssikatos, insider trading, Form 4, stock sale, 10b5-1 plan, Chief Scientific Officer, beneficial ownership